Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
2500 participants
OBSERVATIONAL
2022-11-07
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Visual assessment of the severity of coronary stenosis is known to have a poor diagnostic accuracy for identifying functionally significant lesion \[1,2). The fractional flow reserve (FFR) is an index that quantifies the hemodynamic impact of a stenosis in an epicardial coronary artery. It is defined as the ratio of hyperemic myocardial flow in the presence of stenosis to the hyperemic flow in its absence, and is obtained by measuring the distal coronary pressure and the aortic pressure, respectively, using a pressure-measuring guidewire during maximal hyperemia \[2,3\]. Clinical outcome studies have shown that medical therapy should be preferred for non-hemodynamically significant lesions (FFR\>0.80), and coronary revascularization should be considered in cases of significant functional stenosis (FFR≤0.80) \[4-11\]. Accordingly, both American and European revascularization guidelines recommend using FFR to guide coronary revascularization, especially in stable coronary artery disease patients \[12,13\]. In spite of these recommendations, the utilization of FFR in clinical practice remains low \[14\]. Recently, methods to calculate angiogram based FFR (abFFR) (without the need for pressure wires or induction of maximal coronary hyperemia) have become available. A meta-analysis of 14 studies examining various abFFR technologies ( total of 1,842 lesions), reported a sensitivity of 89%, specificity of 90%, and a C-statistic of 0.84 compared to wire based FFR (wbFFR) \[15\], highlighting the potential for abFFR technologies to facilitate the integration of physiologic assessment into daily cathlab practice. The FFRangioTM system (CathWorks, Kfar-Saba, Israel; Figure 1), is an angiogram-derived FFR technology that has shown excellent diagnostic performance (overall accuracy 92.6%) when compared to wire based FFR in a large pooled cohort of individual patients data from 5 individual studies (588 patients, 700 lesions) \[16\]. FFRangio has already received FDA 510(k) clearance for clinical use as a stand-alone technology without the need for concurrent wire based FFR measurement \[17\]. FFRangio has been in clinical use in Japan since 2019, but there is very limited data on the clinical outcomes of FFRangio guided treatment.
Recently, the first study examining the outcomes of FFRangio guided treatment for patients undergoing angiography for suspected coronary artery disease has reported excellent 1 year results for both FFRangio guided revascularization as well as deferral \[18\], but more data is needed to more appropriately assess the technology in real world patients.
The aim of this multicenter registry is to expand the evidence base on outcomes of FFRangio guided treatment for coronary artery disease, focusing on outcomes of Japanese patients.
Methods:
A retrospective, multicenter registry of consecutive patients in whom FFRangio is used to assess the physiologic significance of at least 1 coronary lesion and guide the treatment decisions .
Inclusion criteria:
• Patients undergoing coronary angiogram for a clinical indication, for whom FFRangio is used to assess the physiologic significance of at least 1 coronary lesion and guide the treatment decisions.
Exclusion criteria:
* Culprit lesion of a STEMI (patients undergoing PCI for non-culprit lesions can be included if the culprit lesion has been successfully treated prior to the non-culprit PCI
* Presence of significant (moderate+) valvular heart disease
* Chronic total occlusion in one of the coronary arteries
* Isolated significant left main disease
* Prior coronary artery bypass graft surgery
* Clinical presentation of cardiogenic shock or severe LV dysfunction
* Coronary anomalies
Endpoints
Primary endpoint:
• composite of all cause death/myocardial infarction(MI)/repeat revascularization(RR) at 1 year follow up.
Secondary endpoints:
* The individual components of the primary endpoint
* Cardiovascular (CV) death
* Urgent RR (performed as an inpatient during an admission for ACS).
* Target vessel RR
* Target lesion RR
* Target vessel MI
* Target lesion MI
Timing of follow up:
Six and 12 months post procedure (primary analysis will include 1 year data) and yearly follow up thereafter up to 5 years.
Ascertainment and adjudications of clinical events The clinical endpoints events will be identified by the participating centres through the patients' electronic medical record and will be further verified, when possible, by interviews conducted during in person/virtual outpatient clinic visits and/or telephone follow up.
Sample size Our aim is to include up to 10 high volume FFRangio centres from Japan and Israel with a goal of reaching a sample size of at least 1,500 patients.
Ethical aspects The study will be approved by the local institutional review boards at each participating centre. Since there is no intervention in the clinical care given to the patient, waiver of the need for patient's informed consent will besought from the IRB/EC.
If participating investigators come by patients' personal information ( information on living individuals that can be used to specific individuals by name, date of birth or other description), such information shall be treated and protected under strict confidentiality. Further more participating investigators shall conduct this research in accordance with ethical principles on the Declaration of Helsinki.
Expected time frame Initiation of registry: Q4 2022 Expected data collection for 1,500 patients: Q2 2023 Initial data analysis: Q3 2023 (median follow up of 6 months for a sample size of 1,500 patients )
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Revascularization
Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are referred for coronary revascularization (PCI/CABG).
FFRangio
Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
Deferral
Patients undergoing angiogram in which FFRangio is used to assess the physiologic significance of at least one coronary lesion, and based on this assessment are assigned to conservative management (optimal guidelines directed medical treatment).
FFRangio
Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FFRangio
Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Presence of significant (moderate+) valvular heart disease
* Chronic total occlusion in one of the coronary arteries
* Isolated significant left main disease
* Prior coronary artery bypass graft surgery
* Clinical presentation of cardiogenic shock or severe LV dysfunction
* Coronary anomalies
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gifu Heart Center
OTHER
Fukuoka Sanno Hospital
UNKNOWN
Saga-ken Medical Center Koseikan
UNKNOWN
Sakakibara Heart Institute
OTHER
Fukuyama Cardiovascular Hospital
UNKNOWN
Ichinomiya-Nishi Hospital
UNKNOWN
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guy Witberg
Consultant inteventional cardiologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Witberg, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Rabin Medical Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rabin Medical Centre
Petah Tikva, , Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dan K, Witberg G, Itabashi F, Maeda T, Kikuta Y, Okabe K, Tanigaki T, Nanasato M, Hikichi Y, Yokoi H, Kornowski R, Matsuo H. Comparison of angiogram-based physiological assessment system sizing tool and intravascular ultrasound imaging measurements. Cardiovasc Revasc Med. 2025 Sep;78:80-85. doi: 10.1016/j.carrev.2025.03.012. Epub 2025 Mar 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RMC-12-2022
Identifier Type: -
Identifier Source: org_study_id